The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
Open accessAbstract
Aims: Sarcomeric gene mutations frequently underlie hypertrophic cardiomyopathy (HCM), a prevalent and complex condition leading to left ventricle thickening and heart dysfunction. We evaluated isogenic genome-edited human pluripotent stem cell-cardiomyocytes (hPSC-CM) for their validity to model, and add clarity to, HCM. Methods and results: CRISPR/Cas9 editing produced 11 variants of the HCM-causing mutation c.C9123T-MYH7 [(p.R453C-β-myosin heavy chain (MHC)] in 3 independent hPSC lines. Isogenic sets were differentiated to hPSC-CMs for high-throughput, non-subjective molecular and functional assessment using 12 approaches in 2D monolayers and/or 3D engineered heart tissues. Although immature, edited hPSC-CMs exhibited the main hallmarks of HCM (hypertrophy, multi-nucleation, hypertrophic marker expression, sarcomeric disarray). Functional evaluation supported the energy depletion model due to higher metabolic respiration activity, accompanied by abnormalities in calcium handling, arrhythmias, and contraction force. Partial phenotypic rescue was achieved with ranolazine but not omecamtiv mecarbil, while RNAseq highlighted potentially novel molecular targets. Conclusion: Our holistic and comprehensive approach showed that energy depletion affected core cardiomyocyte functionality. The engineered R453C-βMHC-mutation triggered compensatory responses in hPSC-CMs, causing increased ATP production and αMHC to energy-efficient βMHC switching. We showed that pharmacological rescue of arrhythmias was possible, while MHY7: MYH6 and mutant: wild-type MYH7 ratios may be diagnostic, and previously undescribed lncRNAs and gene modifiers are suggestive of new mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
Structural and Functional Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells
Lundy, S. D., Zhu, W.-Z., Regnier, M., & Laflamme, M. A. (2013) · Stem Cells and Development · doi:10.1089/scd.2012.0490 · Cited by 738
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy
Sun, N., Yazawa, M., Liu, J., Han, L., Sanchez-Freire, V., Abilez, O. J., Navarrete, E. G., Hu, S., Wang, L., Lee, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003552 · Cited by 696
Maron, B. J., Ommen, S. R., Semsarian, C., Spirito, P., Olivotto, I., & Maron, M. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.003 · Cited by 652
Matsa, E., Rajamohan, D., Dick, E., Young, L., Mellor, I., Staniforth, A., & Denning, C. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr073 · Cited by 389
Self-citationDenning, C., Borgdorff, V., Crutchley, J., Firth, K. S. A., George, V., Kalra, S., Kondrashov, A., Hoang, M. D., Mosqueira, D., Patel, A., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.014 · Cited by 293 · cited 1×
“logically relevant approach to dissect the mechanics of disease and identify new targets for pharmacological intervention.(14) While previous MYH7-HCM animal models provided insight into the disease,(15,16)”
Self-citationStudy familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells
Han, L., Li, Y., Tchao, J., Kaplan, A. D., Lin, B., Li, Y., Mich-Basso, J., Lis, A., Hassan, N., London, B., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu205 · Cited by 191
Human engineered heart tissue as a model system for drug testing
Eder, A., Vollert, I., Hansen, A., & Eschenhagen, T. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.010 · Cited by 190 · cited 1×
“Human engineered heart tissues (hEHTs) directly measure contraction force by partially recapitulating the 3D architecture of cardiac tissue by imposing the auxotonic tension present in vivo.(53,54) We produced hEHTs from AT1 and REBL-PAT isogenics (Figure 6A, B), wherein cardiomyocytes exhibited excellent alignment (S…”
Self-citationGenomic correction of familial cardiomyopathy in human engineered cardiac tissues
Stillitano, F., Turnbull, I. C., Karakikes, I., Nonnenmacher, M., Backeris, P., Hulot, J.-S., Kranias, E. G., Hajjar, R. J., & Costa, K. D. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw307 · Cited by 77
Cited by
Toepfer, C. N., Garfinkel, A. C., Venturini, G., Wakimoto, H., Repetti, G., Alamo, L., Sharma, A., Agarwal, R., Ewoldt, J. K., Cloonan, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.042339 · Cited by 325
Goldfracht, I., Protze, S., Shiti, A., Setter, N., Gruber, A., Shaheen, N., Nartiss, Y., Keller, G., & Gepstein, L. (2020) · Nature Communications · doi:10.1038/s41467-019-13868-x · Cited by 263
Modeling Cardiovascular Diseases with hiPSC-Derived Cardiomyocytes in 2D and 3D Cultures
Sacchetto, C., Vitiello, L., de Windt, L. J., Rampazzo, A., & Calore, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093404 · Cited by 91
Parrotta, E. I., Lucchino, V., Scaramuzzino, L., Scalise, S., & Cuda, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124354 · Cited by 88
Zhuang, R. Z., Lock, R., Liu, B., & Vunjak-Novakovic, G. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00885-3 · Cited by 84
Metadata
- Authors
- Mosqueira, D., Mannhardt, I., Bhagwan, J. R., Lis-Slimak, K., Katili, P., Scott, E., Hassan, M., Prondzynski, M., Harmer, S. C., Tinker, A., Smith, J. G. W., Carrier, L., Williams, P. M., Gaffney, D., Eschenhagen, T., Hansen, A., & Denning, C.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-08
- Volume
- 39
- Issue
- 43
- Pages
- 3879-3892
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2800692959
- Cited by
- 238
- References
- 9
- FWCI
- 17.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. https://app.cochat.ai/papers/10.1093/eurheartj/ehy249
- The paper
- Mosqueira, D., Mannhardt, I., Bhagwan, J. R., Lis-Slimak, K., Katili, P., Scott, E., Hassan, M., Prondzynski, M., Harmer, S. C., Tinker, A., Smith, J. G. W., Carrier, L., Williams, P. M., Gaffney, D., Eschenhagen, T., Hansen, A., & Denning, C. (2018). CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. European Heart Journal. https://doi.org/10.1093/eurheartj/ehy249
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.